# Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma

> **NCT07476326** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Biocon Biologics UK PLC** · enrollment: 120 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Bmab1700
- **DRUG:** Opdivo

## Key facts

- **NCT ID:** NCT07476326
- **Lead sponsor:** Biocon Biologics UK PLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-01
- **Primary completion:** 2027-08-16
- **Final completion:** 2028-02-16
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07476326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07476326, "Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07476326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*